Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial.

Pignone MP, Howard K, Brenner AT, Crutchfield TM, Hawley ST, Lewis CL, Sheridan SL.

JAMA Intern Med. 2013 Mar 11;173(5):362-8. doi: 10.1001/jamainternmed.2013.2651.

2.

A comparison of US and Australian men's values and preferences for PSA screening.

Howard K, Brenner AT, Lewis C, Sheridan S, Crutchfield T, Hawley S, Nielsen ME, Pignone MP.

BMC Health Serv Res. 2013 Oct 5;13:388. doi: 10.1186/1472-6963-13-388.

3.

Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia.

Brenner A, Howard K, Lewis C, Sheridan S, Crutchfield T, Hawley S, Reuland D, Kistler C, Pignone M.

J Gen Intern Med. 2014 Mar;29(3):507-13. doi: 10.1007/s11606-013-2701-0. Epub 2013 Nov 23.

4.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

5.

Pairing physician education with patient activation to improve shared decisions in prostate cancer screening: a cluster randomized controlled trial.

Wilkes MS, Day FC, Srinivasan M, Griffin E, Tancredi DJ, Rainwater JA, Kravitz RL, Bell DS, Hoffman JR.

Ann Fam Med. 2013 Jul-Aug;11(4):324-34. doi: 10.1370/afm.1550.

6.

The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team.

Flood AB, Wennberg JE, Nease RF Jr, Fowler FJ Jr, Ding J, Hynes LM.

J Gen Intern Med. 1996 Jun;11(6):342-9.

PMID:
8803740
7.

Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.

Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, Griffiths J, Jones M, Williams J, Grol R, Elwyn G.

J Med Internet Res. 2010 Aug 6;12(3):e27. doi: 10.2196/jmir.1305.

8.

Physician communication regarding prostate cancer screening: analysis of unannounced standardized patient visits.

Feng B, Srinivasan M, Hoffman JR, Rainwater JA, Griffin E, Dragojevic M, Day FC, Wilkes MS.

Ann Fam Med. 2013 Jul-Aug;11(4):315-23. doi: 10.1370/afm.1509.

9.

Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial.

Gattellari M, Ward JE.

J Med Screen. 2003;10(1):27-39. Erratum in: J Med Screen. 2004;11(4):211.

PMID:
12790313
10.

Shared decision making in prostate-specific antigen testing: the effect of a mailed patient flyer prior to an annual exam.

Landrey AR, Matlock DD, Andrews L, Bronsert M, Denberg T.

J Prim Care Community Health. 2013 Jan;4(1):67-74. doi: 10.1177/2150131912447074. Epub 2012 May 16.

PMID:
23799692
11.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

12.

Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?

O'Dell KJ, Volk RJ, Cass AR, Spann SJ.

J Fam Pract. 1999 Sep;48(9):682-8.

PMID:
10498074
13.

The impact of informed consent on patient interest in prostate-specific antigen screening.

Wolf AM, Nasser JF, Wolf AM, Schorling JB.

Arch Intern Med. 1996 Jun 24;156(12):1333-6.

PMID:
8651843
14.

Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.

Squiers LB, Bann CM, Dolina SE, Tzeng J, McCormack L, Kamerow D.

Am J Prev Med. 2013 Aug;45(2):182-9. doi: 10.1016/j.amepre.2013.04.005.

PMID:
23867025
15.

Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.

Carey M, Bryant J, Yoong SL, Russell G, Barker D, Sanson-Fisher R.

BMC Fam Pract. 2013 Dec 9;14:186. doi: 10.1186/1471-2296-14-186.

16.

Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.

Thomas R, Glasziou P, Rychetnik L, Mackenzie G, Gardiner R, Doust J.

BMJ Open. 2014 Dec 24;4(12):e005691. doi: 10.1136/bmjopen-2014-005691.

17.

Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.

Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.

Ann Intern Med. 2013 May 21;158(10):761-9. doi: 10.7326/0003-4819-158-10-201305210-00633.

PMID:
23567643
18.

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, Lane JA, Peters TJ.

BJU Int. 2006 Oct;98(4):777-82.

19.

Conjoint analysis versus rating and ranking for values elicitation and clarification in colorectal cancer screening.

Pignone MP, Brenner AT, Hawley S, Sheridan SL, Lewis CL, Jonas DE, Howard K.

J Gen Intern Med. 2012 Jan;27(1):45-50. doi: 10.1007/s11606-011-1837-z. Epub 2011 Aug 26.

20.

The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.

Salkeld G, Cunich M, Dowie J, Howard K, Patel MI, Mann G, Lipworth W.

PLoS One. 2016 Apr 6;11(4):e0152999. doi: 10.1371/journal.pone.0152999. eCollection 2016.

Items per page

Supplemental Content

Write to the Help Desk